Why the study?
How adherent is clinical practice to recommended monitoring parameters for amiodarone-induced toxicity?
How adherent is clinical practice to recommended monitoring parameters for amiodarone-induced toxicity?
While overall adherence to amiodarone monitoring criteria was high (91%), specific areas such as photosensitivity warnings, digoxin dose adjustments, and routine slit-lamp exams were frequently overlooked.
Answers are grounded in this paper and cite their sources.
Reassuring high adherence to amiodarone monitoring in this cohort; leaves open targeted quality improvement for specific overlooked parameters.
Amiodarone, an antiarrhythmic drug with predominantly class III effects, has demonstrated serious adverse drug reactions and interactions. The Departments of Pharmacy and Cardiology retrospectively evaluated the monitoring parameters at this institution. Criteria based on current literature were developed. Twenty-six patients were administered amiodarone, qualifying for entry into the audit. Of these patients, seven were excluded because their medical records were unavailable or incomplete. The 19 eligible patients were hospitalized during initiation of therapy and followed in the Outpatient Cardiology Clinic. The collected data extracted from the medical charts were compared with the following elements of the criteria selected: baseline evaluation prior to the start of therapy; monitoring for signs of pulmonary, hepatic, thyroid, cardiac, ophthalmologic, neurologic, and dermatologic toxicity; and evaluation of potential drug interactions with digoxin and warfarin-type anticoagulants. The percentage of criteria elements appropriately monitored on each patient ranged from 82 to 100 percent, with an average of 91 percent. The most frequently overlooked parameters were warning the patient of a possible photosensitivity reaction, decreasing the digoxin dose if the patient was concurrently taking amiodarone, and performing a slit-lamp examination every six months. Frequent examination of the patient's total organ system and laboratory tests, in addition to patient education, are essential to safe monitoring of amiodarone therapy.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: